Navigation Links
Potential treatment target identified in an animal model of pancreatic cancer
Date:7/1/2012

Detailed analysis of genes expressed in circulating tumor cells (CTCs) -- cells that break off from solid tumors and travel through the bloodstream -- has identified a potential treatment target in metastatic pancreatic cancer. In a report that will appear in Nature and has received advance online publication, Massachusetts General Hospital (MGH) Cancer Center investigators describe finding increased expression of WNT2, a member of a known family of oncogenes, in CTCs from a mouse model of the deadly tumor and from human patients. The researchers were able to capture the CTCs - present in the bloodstream at extremely low levels - using a microchip-based device previously developed by members of the team.

"This proof of principle study is the first to show that, by studying both mouse and human pancreatic cancer cells captured with this device, we can dissect genes that are overexpressed in these cells and identify signaling pathways that allow them to survive in the bloodstream," says Daniel Haber, MD, PhD, director of the MGH Cancer Center and senior author of the Nature paper. "We also found that targeting a key step in these pathways can reduce metastatic potential, which is critically important for control of pancreatic cancer. This study would not have been possible without a way to isolate rare CTCs from both mouse models and human patients."

Using the second-generation version of the CTC-chip, developed in collaboration with the MGH Center for Engineering in Medicine, the researchers first captured CTCs from mice genetically programmed to develop pancreatic cancer, one of the most deadly tumors since it is rarely diagnosed before spreading. Analysis of RNA expression levels in pancreatic CTCs, in primary tumor cells, and in normal pancreatic tissue identified several genes with significantly increased expression in the CTCs. One of these, WNT2, belongs to a family of developmental genes often overexpressed in cancer, and
'/>"/>

Contact: Sue McGreevey
smcgreevey@partners.org
617-724-2764
Massachusetts General Hospital
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. Gene sequencing project identifies potential drug targets in common childhood brain tumor
2. Device implanted in brain has therapeutic potential for Huntingtons disease
3. Bioinformatics experts at the CNIO explore additional coding potential hidden in the human genome
4. Mutations in JAK3 gene identified in subtype of lymphoma provide potential drug target
5. Misuse of over-the-counter pain medication is potential health threat
6. VCU Massey Cancer Center sees potential in novel leukemia treatment
7. Hybrid vaccine demonstrates potential to prevent breast cancer recurrence
8. A closer look at PARP-1 reveals potential new drug targets
9. New study of NIH funding allocations suggests potential efficiency gains
10. UNC study shows potential to revive abandoned cancer drug by nanoparticle drug delivery
11. Army researcher develops potential vaccine carrier
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2013)... 18, 2013 Kimono condoms assorted ... favorite condom store recently announced. Condomania recently added ... large selection of condoms from all over the world. ... easy to try different condom styles from one of ... Kimono’s classic comfortable shape and secure, the new packs ...
(Date:5/18/2013)... 2013 Medical device company, FlexLeg, LLC, last ... anticipated mobility aid with its namesake, the FlexLeg. The ... crutch alternative that injured individuals can use to walk ... can remain active and walk during a typical 6-8 week ... system to ensure those who need the device most are ...
(Date:5/18/2013)... The product liability attorneys at Wright & Schulte have ... nationwide who have sustained serious tendon injuries allegedly caused by ... all part of MDL 2308 and were all filed on ... heard in the U.S. District Court of the Western District ... specializes in defending the rights of those who have suffered ...
(Date:5/17/2013)... (PRWEB) May 17, 2013 Allen J. Schultz, ... gum disease treatment available to residents of San ... of the diseased tissue rather than relying on a scalpel ... FDA cleared laser that works on tightly defined wavelengths to ... and healthy tissue intact. , Only about one in every ...
(Date:5/17/2013)... York, New York (PRWEB) May 17, 2013 ... alleged victims of last year’s Rejuvenate and ABG II Modular-Neck ... Superior Court, Bernstein Liebhard LLP reports. According to court ... hip recall litigation on May 15th, at which time the ... cases now pending in the litigation must submit Fact Sheets ...
Breaking Medicine News(10 mins):Health News:Kimono Condoms Assorted Sampler Packs Now Available at Condomania 2Health News:FlexLeg Begins Offering New Mobility Aid 2Health News:Ten Skechers Lawsuits Filed by Wright & Schulte on Behalf of Consumers Who Sustained Severe Tendon Damage Allegedly Due to Wearing Skechers Shape-Ups 2Health News:Ten Skechers Lawsuits Filed by Wright & Schulte on Behalf of Consumers Who Sustained Severe Tendon Damage Allegedly Due to Wearing Skechers Shape-Ups 3Health News:Ten Skechers Lawsuits Filed by Wright & Schulte on Behalf of Consumers Who Sustained Severe Tendon Damage Allegedly Due to Wearing Skechers Shape-Ups 4Health News:San Clemente, CA Periodontist, Dr. Allen J. Schultz, Now Provides Laser Gum Disease Treatment to Southern Orange County Periodontal Disease Patients 2Health News:Stryker Hip Lawsuit News: Bernstein Liebhard LLP Reports on Recent Case Management Conference in New Jersey Stryker Hip Recall Litigation 2Health News:Stryker Hip Lawsuit News: Bernstein Liebhard LLP Reports on Recent Case Management Conference in New Jersey Stryker Hip Recall Litigation 3
... Gaithersburg, MD On December 14-15, 2010, the U.S. Food ... several scientific issues that may affect the regulation of dental ... to recommend that the FDA conduct further review of the ... a July 2009 Final Rule ( http://bit.ly/FDA2009FinalRule ) from the ...
... , WEDNESDAY, Dec. 22 (HealthDay News) -- New research ... suicide pill: a protein on their surfaces that gives them the ... The challenge now, the researchers say, is to figure out how ... dangerous "don,t eat me" signal. A study published online ...
... A study comparing the long-term outcomes of ... that certain subsets of patients have better long-term ... may result in better survival than proton-beam therapy, ... This is the first study to report the ...
... believe they can beat cancer if it,s described in ... Journal of Consumer Research . The study ... characteristics, intentions, and behavior to nonhuman objects. "The present ... beyond simple liking of products with humanlike physical features," ...
... , TUESDAY, Dec. 21 (HealthDay News) -- Teen births in the ... teenagers fell 6 percent from the previous year to the lowest ... The birth rate for 15- to 19-year-olds, which has declined 16 ... 1,000 teens in 2009, according to a new report from the ...
... important details about a patient,s care during an office ... a whip-smart assistant for physicians a new system ... exam when a patient,s care is amiss. ... care physicians, performance and the health care of patients ...
Cached Medicine News:Health News:AADR testifies to the FDA advisory panel on dental amalgam 2Health News:Cancer Cells May Be Able to Urge Their Own Death 2Health News:Photons vs. protons for treatment of spinal cord gliomas 2Health News:Why do risks with human characteristics make powerful consumers feel lucky? 2Health News:U.S. Teen Birth Rate Hit Record Low in 2009: CDC 2Health News:U.S. Teen Birth Rate Hit Record Low in 2009: CDC 3Health News:Smarter systems help busy doctors remember 2Health News:Smarter systems help busy doctors remember 3
(Date:5/17/2013)... Biotech Ltd. (Nasdaq: SVA ), a leading provider ... that it will release its unaudited financial results for the ... May 28, 2013.  The Company will host a conference call ... 28, 2013 at 8:00 p.m. China Standard Time) to review ... corporate developments. To access the conference call, please ...
(Date:5/16/2013)... and MECHELEN, Belgium , May 17, ... (NYSE: ABBV ) announced today an extension ... disease.  Galapagos will fund and complete a Phase 2 ... rapid progression into Phase 3.  Upon successful completion of ... Galapagos $50 million.  The terms of the collaboration extension ...
(Date:5/16/2013)... May 16, 2013  Today, the National Patient Advocate ... House of Representatives recently approved a bill that ... charging patients higher out-of-pocket fees for newer, more expensive ... which have more severe side-effects. However, the bill was ... which will continue to be a barrier to patients ...
Breaking Medicine Technology:Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results 2Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results 3AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 2AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 3AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 4AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 5AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 6National Patient Advocate Foundation Responds to N.C. State House Approval of Flawed Cancer Treatment Fairness Bill 2National Patient Advocate Foundation Responds to N.C. State House Approval of Flawed Cancer Treatment Fairness Bill 3
... just 21 days, CVS/pharmacy,s ninth annual in-store fundraising campaign to ... $4.1 million. The funds raised by the campaign will be ... the funding of new clinical research aimed at developing new ... of finding a cure for ALS. This donation brings the ...
... Pharmaceuticals, Inc. (Nasdaq: IDIX ), a biopharmaceutical ... for the treatment of human viral diseases, today announced ... the 61st Annual Meeting of the American Association for ... 2010 in Boston, Massachusetts). The abstracts being presented are ...
Cached Medicine Technology:ALS Research Gets a $4.1 Million Boost from CVS/pharmacy Fundraising Campaign 2ALS Research Gets a $4.1 Million Boost from CVS/pharmacy Fundraising Campaign 3Idenix Announces Data Presentations at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) 2Idenix Announces Data Presentations at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) 3
... VITROS HBsAg assay is the ... the U.S. Food and Drug,Administration ... a random,access format on the ... Now you can run an,HBsAg ...
... use as a quality assurance ... M (IgM) antibodies to hepatitis ... IgM antibodies to hepatitis A ... e antigen (HBeAg) and total ...
... antibody gives positive staining of prostatic ... hyperplasia. In cases of prostatic cancer, ... give definite but weak staining or ... cells; this pattern of staining permits ...
... Wampole Laboratories offers a comprehensive line of ... serum and urine in convenient one-step stick ... 2 testing options. Clearview Easy HCG is ... convenient stick format. Clearview HCG II ...
Medicine Products: